HOME
Leading the way to a cure

Research Portfolio Summary

The ALR’s Research Portfolio Summary—
A Vigorous Response to Finding a Cure for Lupus

An ALR Research Portfolio Summary is a synopsis showcasing the breadth of the scientific research investigations that are funded by the organization in a particular year.

Our 2014 Research Portfolio Summary describes 42 investigations being conducted by some of the world’s most brilliant scientists—offering a fascinating glimpse into the possibilities that ALR-funded research has to offer.

The Alliance for Lupus Research is turning what used to be considered “science fiction” into reality by funding dozens of the most daring, innovative research each year. 

Together, these investigations or studies form the ALR Research Portfolio Summary (RPS).  Each Research Portfolio Summary includes a synopsis of all scientific research investigations that are funded by the organization in a particular year. Target Identification in Lupus (TIL), Functional Genomics and Molecular Pathways (FGMP), and special funded projects like SLEGEN and ImmunoChip.

As evidenced by our 2014 Research Portfolio Summary, the ALR is working on many fronts to stop lupus in its tracks.  Our strategy is a coordinated effort—one that leverages resources and avoids duplication of effort and inefficiency. 

The ALR’s objective is to aggressively work to bring treatments from the laboratory to patients’ bedsides in the shortest time possible.  And the scientific investigations that are currently being funded are seeking to identify potential genetic causes of lupus, while developing novel approaches for treatment and prevention. 

 

One of the amazing things about the ALR is the broad portfolio of research projects that it has been able to support. This has really allowed researchers like me to tackle lupus from many different angles—from genetics to molecular mechanisms and translational studies.”

 — Alexandra Pernis, M.D.
Dr. Pernis has received three ALR
grants to propel her work on T cells.

To share these ideas with other scientists, donors, and anyone interested in learning more about the specific types of studies that the ALR is funding, the current ALR Research Portfolio Summary and several summaries from prior years are available on the ALR website. 

These ALR-funded studies run the gamut of scientific exploration—from looking to replace diseased immune cells with healthy ones … to understanding why the majority of people with lupus will develop kidney problems … to deleting certain cells in the body that trigger immune system reactions.

For a better understanding of these topics—and all 42 investigations currently being funded by the ALR, please read our
2014 Research Portfolio Summary

For a look at earlier ALR-funded research, please click on the year you are interested in seeing.

Go to our 2013 Research Portfolio Summary

Go to our 2012 Research Portfolio Summary.

Go to our 2011 Research Portfolio Summary.

Go to our 2010 Research Portfolio Summary.

Go to our 2009 Research Portfolio Summary.

Go to our 2007 Research Portfolio Summary.

Go to our 2006 Research Portfolio Summary.

Go to our 2005 Research Portfolio Summary.

Go to our 2004 Research Portfolio Summary.


Since its founding, ALR has given more money to lupus research than any non-governmental agency in the world; to date, ALR has committed almost $90 million to lupus research. Below is a list of our Lupus Research Funding mechanisms:
For a Downloadable list of our current grants Click Here


Target Identification in Lupus (TIL) SUMMARY

Accelerating Progress Toward More Effective Treatments

Our TIL grant mechanisms give world-class researchers the opportunity to investigate promising studies through the funding mechanism of large grants for a period of two years. The aim of all lupus research funded under the TIL program is to quickly move a therapy from the laboratory to the patient’s bedside.

The ALR Scientific Advisory Board determines if an investigation is worthy of a TIL grant, which can be as much as $400,000. TIL grantees also have the opportunity to apply for continued funding up to $200,000.

Click here to learn more about our TIL awardees


Functional Genomics and Molecular Pathways (FGMP) in SLE Grant SUMMARY*

Blazing New Avenues of Discovery

These studies, in uncovering a greater level of detail in how the immune system works, are expanding the list of therapeutic targets.

Selected investigators receive research grants of up to $350,000 for two years or Pilot Grants of up to $75,000 for one year. Grantees will focus on determining how the genes identified by SLEGEN may have a role in the disease, and provide further information about the molecular pathways modulated by these genes.

Click here to learn more about our FGMP awardees

*We are currently not funding any new grants under the Functional Genomics and Molecular Pathways in SLE mechanism.


SLEGEN Consortium — ImmunoChip Study SUMMARY

Revolutionizing Lupus Research

Launched in 2005, this special initiative is designed to accelerate the search for genes that put people at risk for developing systemic lupus erythematosus (SLE or lupus). The SLEGEN Initiative facilitates this by pooling patient samples collected from the International SLE Genetics Consortium, which includes many scientists working on the genetics of lupus.

Click here to learn more about the SLEGEN initiative


Lupus Insight Prize

For the second year, the Alliance for Lupus Research (ALR), the Lupus Foundation of America (LFA) , and the Lupus Research Institute (LRI) will again join together to encourage scientific advances in lupus research. The Lupus Insight Prize, a novel collaborative initiative among the three organizations, will recognize and honor an outstanding investigator with a documented record of creativity, innovation, and productivity in lupus investigations, and with a high likelihood of generating further advances in the diagnosis and treatment of the disease. Lupus is an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. The Lupus Insight Prize will be awarded annually by the sponsoring organizations.

Click here to learn more about the Lupus Insight Prize


Pfizer’s Centers for Therapeutic Innovation (CTI)

Alliance for Lupus Research (ALR) and Pfi zer’s Centers for Therapeutic Innovation (CTI) are partnering to discover new therapies for patients living with lupus. As part of this fi rst-of-its-kind collaboration in lupus, ALR and CTI are co-funding novel translational research projects primarily driven by leading academic medical centers within the CTI network. Grants are awarded up to two years for a maximum of $500,000.

CTI’s goal and that of the ALR in this partnership is the same – to provide new, targeted therapies to patients living with lupus. Our hope is that by combining our resources we can speed the creation of life-saving treatments for patients who need them.


1.5 million

people in the U.S. have Lupus.

100 million

dollars committed to lupus research by the Alliance for Lupus Research.


We're walking across the United States to raise awareness and funds for lupus research.

Can't make it? Join our National Virtual Walk to participate anytime, anywhere.


Show your support by visiting the Alliance for Lupus Research online store. Discover the perfect gift, or prepare for a walk with our selection of apparel and accessories.

Powered by Convio
nonprofit software